The FDA has approved Enbumyst offering a self-administered outpatient option for managing edema in patients with heart failure, liver disease, and kidney disease.
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.